The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XXIV.a

Pneumonitis (interstitial lung disease/ILD)

See Elu et al. Eur Respir J in press, 2026

Publications

Bacon H, Ye XY, Liu ZA, Lee G, Hahn E, Amir E, Tadic T, Hope A, Koch CA

Predictors of pneumonitis in patients treated with systemic therapy and radiotherapy for localized triple negative or HER2 positive breast cancer.

Breast (Edinburgh, Scotland). 2026;86:104706

O'Sullivan CC, Higgins AS, Alkurashi AK, Ahluwalia V, Taraba JL, McKie PM, Kamath PS, Iyer VN, Haddad TC

Hepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series.

Frontiers in oncology. 2024;14:1434492